S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
S&P 500   0.54 (+5.44%)
DOW   0.54 (+5.44%)
QQQ   271.05 (+0.25%)
AAPL   440.25 (+0.36%)
MSFT   212.94 (-0.16%)
FB   249.12 (-0.28%)
GOOGL   1,479.09 (+0.39%)
AMZN   3,205.03 (+2.11%)
NVDA   451.47 (+0.53%)
CGC   19.21 (-0.57%)
BABA   264.91 (+1.03%)
TSLA   1,485.02 (-0.13%)
MU   51.05 (-0.49%)
GE   6.40 (+4.23%)
AMD   85.31 (+0.32%)
T   29.85 (-0.53%)
F   6.96 (+1.46%)
ACB   10.71 (-0.19%)
GILD   69.00 (-2.65%)
NFLX   502.11 (-1.48%)
DIS   127.61 (+8.80%)
BAC   25.39 (+1.52%)
BA   174.28 (+5.58%)
Log in

NASDAQ:ARQTI-Mab News Headlines

$24.55
-0.42 (-1.68 %)
(As of 08/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$24.21
Now: $24.55
$25.79
50-Day Range
$24.98
MA: $29.87
$36.56
52-Week Range
$17.10
Now: $24.55
$40.88
Volume103,107 shs
Average Volume124,912 shs
Market Capitalization$936.71 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

I-Mab (NASDAQ ARQT) News Headlines

Source:
DateHeadline
Howard G. Welgus Sells 2,800 Shares of I-Mab (NASDAQ:ARQT) StockHoward G. Welgus Sells 2,800 Shares of I-Mab (NASDAQ:ARQT) Stock
americanbankingnews.com - August 5 at 6:26 PM
Bethany Dudek Joins Arcutis as Vice President of QualityBethany Dudek Joins Arcutis as Vice President of Quality
finance.yahoo.com - August 4 at 10:03 AM
The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisThe Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis
finance.yahoo.com - August 3 at 1:55 PM
Preliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque PsoriasisPreliminary Data from Long-Term Safety Study Support Chronic Use of ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
finance.yahoo.com - July 31 at 10:40 AM
Arcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical OfficerArcutis Appoints Patrick Burnett, M.D., Ph.D., FAAD, as Chief Medical Officer
finance.yahoo.com - July 27 at 12:55 PM
I-Mabs (NASDAQ:ARQT) Lock-Up Period Will End  on July 29thI-Mab's (NASDAQ:ARQT) Lock-Up Period Will End on July 29th
www.americanbankingnews.com - July 22 at 1:16 AM
Arcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating  ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp PsoriasisArcutis Enrolls Last Patient in Phase 2b Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Scalp Psoriasis
finance.yahoo.com - July 20 at 9:55 AM
The New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque PsoriasisThe New England Journal of Medicine Publishes Results from Positive Phase 2b Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment of Chronic Plaque Psoriasis
finance.yahoo.com - July 15 at 6:16 PM
Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand EczemaArcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema
finance.yahoo.com - July 13 at 1:25 PM
Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care ConferenceArcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference
finance.yahoo.com - June 10 at 6:27 PM
Ayisha Jeter Joins Arcutis as Vice President of Market AccessAyisha Jeter Joins Arcutis as Vice President of Market Access
finance.yahoo.com - June 1 at 9:15 AM
Halley E. Gilbert Appointed to Arcutis Board of DirectorsHalley E. Gilbert Appointed to Arcutis Board of Directors
finance.yahoo.com - April 27 at 1:25 PM
Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand EczemaArcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema
finance.yahoo.com - April 21 at 1:33 PM
Kimberly Lathroum Joins Arcutis as Vice President of MarketingKimberly Lathroum Joins Arcutis as Vice President of Marketing
finance.yahoo.com - March 23 at 12:37 PM
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque PsoriasisArcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
finance.yahoo.com - March 16 at 9:15 AM
Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual MeetingArcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting
finance.yahoo.com - March 3 at 9:17 AM
Arcutis to Present at the Cowen 40th Annual Health Care ConferenceArcutis to Present at the Cowen 40th Annual Health Care Conference
finance.yahoo.com - February 19 at 2:42 PM
Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque PsoriasisArcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis
finance.yahoo.com - February 13 at 12:24 PM
Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesArcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - February 10 at 8:37 AM
This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.